ME03301B - Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак) - Google Patents
Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак)Info
- Publication number
- ME03301B ME03301B MEP-2019-6A MEP20196A ME03301B ME 03301 B ME03301 B ME 03301B ME P20196 A MEP20196 A ME P20196A ME 03301 B ME03301 B ME 03301B
- Authority
- ME
- Montenegro
- Prior art keywords
- kinasen
- janus
- jak
- pyrrolo
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361767947P | 2013-02-22 | 2013-02-22 | |
| EP17191163.9A EP3290421B1 (en) | 2013-02-22 | 2014-02-11 | Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03301B true ME03301B (me) | 2019-07-20 |
Family
ID=50151346
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-246A ME02904B (me) | 2013-02-22 | 2014-02-11 | DERIVATI PIROLO[2,3 -d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK) |
| MEP-2019-6A ME03301B (me) | 2013-02-22 | 2014-02-11 | Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-246A ME02904B (me) | 2013-02-22 | 2014-02-11 | DERIVATI PIROLO[2,3 -d]PIRIMIDINA KAO INHIBITORI JANUS KINAZA (JAK) |
Country Status (47)
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3311666T (pt) | 2010-08-18 | 2021-06-21 | Biosplice Therapeutics Inc | Dicetonas e hidroxicetonas como ativadores da via de sinalização de catenina |
| DK2948134T3 (da) | 2013-01-24 | 2020-06-02 | Palvella Therapeutics Inc | Sammensætninger til transdermal indgivelse af mtor-inhibitorer |
| AP2015008664A0 (en) | 2013-02-22 | 2015-08-31 | Pfizer | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) |
| JP6401189B2 (ja) | 2013-02-22 | 2018-10-03 | サミュメッド リミテッド ライアビリティ カンパニー | Ｗｎｔ／β−カテニンシグナル伝達経路活性化剤としてのγ−ジケトン |
| WO2016024185A1 (en) * | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
| MX368248B (es) | 2014-08-20 | 2019-09-25 | Samumed Llc | Gamma-dicetonas para tratamiento y prevencion de piel envejecida y arrugas. |
| AU2016271904B2 (en) * | 2015-05-29 | 2018-05-10 | Wuxi Fortune Pharmaceutical Co.,Ltd | Janus kinase inhibitor |
| US11780848B2 (en) | 2015-10-16 | 2023-10-10 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| KR20250010141A (ko) | 2015-10-16 | 2025-01-20 | 애브비 인코포레이티드 | (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법 |
| US12365689B2 (en) | 2015-10-16 | 2025-07-22 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| CN106831779B (zh) * | 2015-11-28 | 2019-07-19 | 南昌弘益药业有限公司 | 一类jak激酶抑制剂的新化合物 |
| JP7096592B2 (ja) | 2016-02-16 | 2022-07-06 | ワシントン・ユニバーシティ | Ｊａｋ阻害剤およびこれらの利用 |
| IL302385B2 (en) | 2017-01-06 | 2024-06-01 | Palvella Therapeutics Inc | Non-aqueous preparations of mTOR inhibitors and methods of use |
| CN108794480A (zh) * | 2017-04-28 | 2018-11-13 | 天津药物研究院有限公司 | 吡咯并嘧啶类化合物、其制备方法和用途 |
| TWI827583B (zh) | 2018-03-08 | 2024-01-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物 |
| WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| EP3817810B1 (en) * | 2018-07-06 | 2025-09-17 | Pfizer Inc. | Manufacturing process and intermediates for a pyrrolo[2,3- d]pyrimidine compound and use thereof |
| CN113272306A (zh) * | 2018-11-05 | 2021-08-17 | 爱维斯塔制药解决方案有限公司 | 化学化合物 |
| AU2019426113B2 (en) | 2019-01-30 | 2022-06-16 | Felicamed Biotechnology Co., Ltd. | JAK inhibitor and preparation method therefor |
| JP7561497B2 (ja) | 2019-02-15 | 2024-10-04 | ファイザー・インク | 結晶性ピリミジニル－３，８－ジアザビシクロ［３．２．１］オクタニルメタノン化合物およびその使用 |
| US12398141B2 (en) | 2019-03-14 | 2025-08-26 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd | JAK kinase inhibitor, preparation method for same, and applications thereof in field of medicine |
| EP3989975A4 (en) * | 2019-06-27 | 2023-09-27 | Glenmark Life Sciences Limited | PROCESS FOR THE PREPARATION OF ABROCITINIB |
| CN114667148A (zh) | 2019-09-11 | 2022-06-24 | 辉瑞公司 | 用jak抑制剂治疗汗腺炎 |
| EP4041241A4 (en) | 2019-09-27 | 2023-09-06 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSIS AND ASSOCIATED CONDITIONS |
| CA3177852A1 (en) | 2020-04-04 | 2021-10-07 | Pfizer Inc. | Methods of treating coronavirus disease 2019 |
| CN113637018A (zh) | 2020-04-27 | 2021-11-12 | 苏州晶云药物科技股份有限公司 | 磺酰胺类化合物的晶型及其制备方法 |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| MX2022014940A (es) * | 2020-05-28 | 2023-01-04 | Pfizer | Derivados de pirrolo[2,3-d]pirimidina. |
| JP2023544490A (ja) * | 2020-09-08 | 2023-10-24 | ガルデルマ ホールディング エスエー | 新規ｊａｋ阻害剤化合物、その合成方法、及びその使用 |
| EP4210828A1 (en) * | 2020-09-11 | 2023-07-19 | Galderma Holding SA | Novel jak inhibitor compounds, method for synthesizing same and use thereof |
| JP2024505910A (ja) | 2021-02-02 | 2024-02-08 | ファイザー・インク | 慢性手湿疹の処置のための投与レジメン |
| KR20230019801A (ko) * | 2021-08-02 | 2023-02-09 | 한국화학연구원 | 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물 |
| CN118255769A (zh) * | 2022-12-28 | 2024-06-28 | 格格巫（珠海）生物科技有限公司 | 一种立体异构体的制备方法及中间体 |
| ES2993658B2 (es) * | 2023-06-27 | 2025-07-02 | Moehs Iberica Sl | (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib |
| WO2025008772A2 (en) | 2023-07-06 | 2025-01-09 | Pfizer Ireland Pharmaceuticals | Improved manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof |
| ES3040374A1 (es) | 2024-04-30 | 2025-10-30 | Moehs Iberica Sl | Cocristales de N-{cis-3-[metil(7H-pirrolo[2,3-d]pirimidin-4-il)amino]ciclobutil}propano-1-sulfonamida |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3037980A (en) | 1955-08-18 | 1962-06-05 | Burroughs Wellcome Co | Pyrrolopyrimidine vasodilators and method of making them |
| KR0173172B1 (ko) | 1992-12-17 | 1999-02-01 | 알렌 제이. 스피겔 | Crf 길항제로서의 피롤로피리미딘 |
| JPH06329675A (ja) | 1993-05-20 | 1994-11-29 | Teijin Ltd | ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体 |
| JPH06329674A (ja) | 1993-05-20 | 1994-11-29 | Teijin Ltd | ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン |
| JPH08134068A (ja) | 1994-11-02 | 1996-05-28 | Teijin Ltd | ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体 |
| US6051578A (en) | 1996-02-12 | 2000-04-18 | Pfizer Inc. | Pyrazolopyrimidines for treatment of CNS disorders |
| US6686366B1 (en) | 1998-06-02 | 2004-02-03 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| KR100415791B1 (ko) | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
| PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
| AU4808300A (en) | 1999-04-30 | 2000-11-17 | Neurogen Corporation | 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands |
| US6664252B2 (en) | 1999-12-02 | 2003-12-16 | Osi Pharmaceuticals, Inc. | 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof |
| NZ518884A (en) | 1999-12-10 | 2004-02-27 | Pfizer Prod Inc | Pyrrolo[2,3-d]pyrimidine compounds |
| US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
| DK1686130T3 (da) | 2000-06-26 | 2009-04-06 | Pfizer Prod Inc | Pyrrolo-[2,3-d]-pyrimidinforbindelser som immunsuppressive midler |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6673802B2 (en) | 2000-12-01 | 2004-01-06 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| DE60234118D1 (de) | 2001-11-30 | 2009-12-03 | Osi Pharm Inc | Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| AU2003299901A1 (en) | 2002-10-04 | 2004-05-04 | Merck And Co., Inc. | Thrombin inhibitors |
| RS20050380A (sr) | 2002-11-21 | 2007-11-15 | Pfizer Products Inc., | Derivati 3-aminopiperidina i postupci njihove proizvodnje |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| DK1913000T3 (da) * | 2005-07-29 | 2012-03-12 | Pfizer Prod Inc | Pyrrolo[2,3-D]pyrimidinderivater; deres mellemprodukter og syntese |
| JP2007091649A (ja) | 2005-09-29 | 2007-04-12 | Taisho Pharmaceut Co Ltd | ピリミジン誘導体及びその使用に関連する治療方法 |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| EA200870385A1 (ru) | 2006-03-29 | 2009-04-28 | Фолдркс Фармасьютикалз, Инк. | Ингибирование токсичности альфа-синуклеина |
| WO2008089307A2 (en) | 2007-01-18 | 2008-07-24 | Lexicon Pharmaceuticals, Inc. | Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US20100331297A1 (en) | 2007-11-07 | 2010-12-30 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| CA2703987A1 (en) | 2007-11-08 | 2009-05-14 | Pfizer Inc. | Cyclobutyl carboxylic acid derivatives |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| CN102131812B (zh) | 2008-08-20 | 2014-04-09 | 硕腾有限责任公司 | 吡咯并[2，3-d]嘧啶化合物 |
| AU2009294290B2 (en) | 2008-09-18 | 2012-08-30 | Pfizer Limited | Amide compounds useful in therapy |
| AU2010308028A1 (en) * | 2009-10-15 | 2012-04-19 | Pfizer Inc. | Pyrrolo[2,3-d] pyrimidine compounds |
| CN108774237A (zh) | 2009-12-01 | 2018-11-09 | Abbvie 公司 | 新的三环化合物 |
| CA2782720A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| MX2012008049A (es) | 2010-01-12 | 2012-08-01 | Hoffmann La Roche | Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,. |
| WO2011104652A2 (en) | 2010-02-24 | 2011-09-01 | Pfizer Inc. | Veterinary compositions |
| CA2805669C (en) | 2010-07-16 | 2018-08-21 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| US9050334B2 (en) | 2010-07-16 | 2015-06-09 | Innov88 Llc | MIF inhibitors and their uses |
| DK2646444T3 (da) | 2010-12-03 | 2016-06-27 | Epizyme Inc | Substituerede purin- og 7-deazapurinforbindelser som modulatorer af epigenetiske enzymer |
| US8987307B2 (en) | 2011-03-03 | 2015-03-24 | Hoffmann-La Roche Inc. | 3-amino-pyridines as GPBAR1 agonists |
| JP2014510708A (ja) | 2011-06-07 | 2014-05-01 | 大日本住友製薬株式会社 | インダゾール誘導体およびピロロピリジン誘導体ならびにその医薬用途 |
| JP2013010719A (ja) | 2011-06-30 | 2013-01-17 | Dainippon Sumitomo Pharma Co Ltd | ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途 |
| RU2618673C2 (ru) * | 2011-12-21 | 2017-05-10 | Цзянсу Хэнжуй Медсин Ко., Лтд. | Производные пирролопиримидина, полезные в качестве ингибиторов jak-киназы |
| US20140018361A1 (en) | 2012-07-11 | 2014-01-16 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| SI2874630T1 (sl) | 2012-07-20 | 2019-04-30 | Zoetis Services Llc | Odmerni režim inhibitorjev Janus kinaz (JAK) |
| JP2014133739A (ja) | 2012-12-12 | 2014-07-24 | Dainippon Sumitomo Pharma Co Ltd | インダゾール誘導体またはピロロピリジン誘導体からなる医薬 |
| AP2015008664A0 (en) | 2013-02-22 | 2015-08-31 | Pfizer | Pyrrolo [2,3-D] pyrimidine derivatives as inhibitors of janus-related kinases (JAK) |
| WO2016024185A1 (en) | 2014-08-12 | 2016-02-18 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase |
-
2014
- 2014-02-11 AP AP2015008664A patent/AP2015008664A0/xx unknown
- 2014-02-11 HU HUE17191163A patent/HUE041778T2/hu unknown
- 2014-02-11 PT PT147058879T patent/PT2958921T/pt unknown
- 2014-02-11 JP JP2015558572A patent/JP6145179B2/ja active Active
- 2014-02-11 ES ES17191163T patent/ES2713052T3/es active Active
- 2014-02-11 MD MDA20150073A patent/MD4735C1/ro active IP Right Grant
- 2014-02-11 ME MEP-2017-246A patent/ME02904B/me unknown
- 2014-02-11 LT LTEP14705887.9T patent/LT2958921T/lt unknown
- 2014-02-11 MY MYPI2015702431A patent/MY177476A/en unknown
- 2014-02-11 HR HRP20171599TT patent/HRP20171599T2/hr unknown
- 2014-02-11 PE PE2015001766A patent/PE20151764A1/es active IP Right Grant
- 2014-02-11 EA EA201591255A patent/EA027879B1/ru unknown
- 2014-02-11 MA MA38347A patent/MA38347A1/fr unknown
- 2014-02-11 RS RS20190097A patent/RS58245B1/sr unknown
- 2014-02-11 PL PL14705887T patent/PL2958921T3/pl unknown
- 2014-02-11 NZ NZ710411A patent/NZ710411A/en unknown
- 2014-02-11 SI SI201431068T patent/SI3290421T1/sl unknown
- 2014-02-11 KR KR1020157022489A patent/KR101787858B1/ko active Active
- 2014-02-11 MX MX2015010928A patent/MX374338B/es active IP Right Grant
- 2014-02-11 LT LTEP17191163.9T patent/LT3290421T/lt unknown
- 2014-02-11 ES ES14705887.9T patent/ES2647525T3/es active Active
- 2014-02-11 SG SG11201505816UA patent/SG11201505816UA/en unknown
- 2014-02-11 DK DK14705887.9T patent/DK2958921T3/da active
- 2014-02-11 CU CUP2015000078A patent/CU24275B1/xx unknown
- 2014-02-11 PL PL17191163T patent/PL3290421T3/pl unknown
- 2014-02-11 ME MEP-2019-6A patent/ME03301B/me unknown
- 2014-02-11 WO PCT/IB2014/058889 patent/WO2014128591A1/en not_active Ceased
- 2014-02-11 CA CA2900703A patent/CA2900703C/en active Active
- 2014-02-11 CN CN201480009783.8A patent/CN105008362B/zh active Active
- 2014-02-11 HU HUE14705887A patent/HUE037192T2/hu unknown
- 2014-02-11 AU AU2014220357A patent/AU2014220357B2/en active Active
- 2014-02-11 RS RS20171095A patent/RS56503B1/sr unknown
- 2014-02-11 CN CN201710440379.1A patent/CN107089985B/zh active Active
- 2014-02-11 EP EP17191163.9A patent/EP3290421B1/en active Active
- 2014-02-11 DK DK17191163.9T patent/DK3290421T3/en active
- 2014-02-11 GE GEAP201413916A patent/GEP201606600B/en unknown
- 2014-02-11 SI SI201430459T patent/SI2958921T1/sl unknown
- 2014-02-11 EP EP14705887.9A patent/EP2958921B1/en active Active
- 2014-02-11 BR BR112015019634-9A patent/BR112015019634B1/pt active IP Right Grant
- 2014-02-11 PT PT17191163T patent/PT3290421T/pt unknown
- 2014-02-11 TR TR2019/02525T patent/TR201902525T4/tr unknown
- 2014-02-19 TW TW103105469A patent/TWI507408B/zh active
- 2014-02-19 US US14/183,946 patent/US9035074B2/en active Active
- 2014-02-20 UY UY0001035337A patent/UY35337A/es not_active Application Discontinuation
- 2014-02-21 AR ARP140100561A patent/AR094857A1/es active IP Right Grant
- 2014-09-24 NO NO14789648A patent/NO3052752T3/no unknown
- 2014-11-02 UA UAA201507511A patent/UA111804C2/uk unknown
-
2015
- 2015-04-21 US US14/691,606 patent/US9545405B2/en active Active
- 2015-05-18 US US14/715,046 patent/US9549929B2/en active Active
- 2015-07-23 IL IL240132A patent/IL240132B/en active IP Right Grant
- 2015-07-29 ZA ZA2015/05454A patent/ZA201505454B/en unknown
- 2015-07-30 CR CR20150395A patent/CR20150395A/es unknown
- 2015-08-12 PH PH12015501779A patent/PH12015501779A1/en unknown
- 2015-08-17 CL CL2015002303A patent/CL2015002303A1/es unknown
- 2015-08-18 TN TN2015000355A patent/TN2015000355A1/fr unknown
- 2015-08-21 DO DO2015000206A patent/DOP2015000206A/es unknown
-
2017
- 2017-05-11 JP JP2017094676A patent/JP2017165762A/ja active Pending
- 2017-10-26 CY CY20171101116T patent/CY1119502T1/el unknown
-
2019
- 2019-01-23 HR HRP20190152TT patent/HRP20190152T1/hr unknown
- 2019-01-30 CY CY20191100127T patent/CY1121468T1/el unknown
-
2021
- 2021-12-22 NL NL301155C patent/NL301155I2/nl unknown
-
2022
- 2022-01-12 CY CY2022003C patent/CY2022003I2/el unknown
- 2022-01-17 HU HUS2200003C patent/HUS2200003I1/hu unknown
- 2022-01-26 LT LTPA2022502C patent/LTC2958921I2/lt unknown
- 2022-02-01 NO NO2022004C patent/NO2022004I1/no unknown
- 2022-02-10 FR FR22C1006C patent/FR22C1006I2/fr active Active
- 2022-05-13 LU LU00261C patent/LUC00261I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03301B (me) | Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак) | |
| EP3013798A4 (en) | Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors | |
| ZA201505011B (en) | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith | |
| ZA201507874B (en) | 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors | |
| EA201691164A1 (ru) | Производные пиразоло[1,5-a]пиридина и способы их применения | |
| EP2916836A4 (en) | AMINOPYRIDE-CONTAINING MILK TYROSINE KINASE (SYK) INHIBITOR | |
| PT3041475T (pt) | Compostos baseados em pirazolo[1,5-a]pirimidina, composições compreendendo-os e métodos da sua utilização | |
| EA201690716A1 (ru) | ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ | |
| IL244817A0 (en) | Transmuted pyrimidine compounds and their use as syk inhibitors |